HG-204

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameHG-204
Drug Alias NameHG-204HG204AAV-hfCas13Y-gMECP2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas13Cell and gene therapy > Gene therapy > Gene editing > RNA editing
Mechanisms of ActionMethyl-CpG-binding protein 2 inhibitors
TargetsMethyl-CpG-binding protein 2
Therapy Area/IndicationsLubs X-linked mental retardation syndromeNeurodevelopmental Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Beijing UniversityHuidaGene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLubs X-linked mental retardation syndromeNeurodevelopmental Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A